Reportlinker Adds World Bulk Paclitaxel Market Report

NEW YORK--(Business Wire)--
Reportlinker.com announces that a new market research report is available in its
catalogue.

World Bulk Paclitaxel Market

http://www.reportlinker.com/p098262/World-Bulk-Paclitaxel--Market.html

This report analyzes the worldwide markets for Bulk Paclitaxel in kilograms and
US$ Million. The report provides separate comprehensive analytics for the US,
and Rest of World. Annual forecasts are provided for the period of 2000 through
2015. The report profiles 35 companies including many key and niche players
worldwide such as Abraxis BioScience, Inc., Bioxel Pharma, Inc., Bristol-Myers
Squibb Co., Hospira, Inc., Indena S.p.A., OncoGenex Pharmaceuticals, Inc., Teva
Pharmaceuticals USA, Inc., and Xechem International Inc. Market data and
analytics are derived from primary and secondary research. Company profiles are
mostly extracted from URL research and reported select online sources.

BULK PACLITAXEL MCP-1208 A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data
Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. Industry Overview II-1 Paclitaxel - Leading from the Front II-1 US Market -
Magnificently Outdistancing Others II-1 Cancer Blockbusters - Facing the Brunt
II-1 A Sunrise Opportunity II-1 BMS` Reign Comes to an End II-2 Exploring New
Avenues II-2 Falling Prices - Boon for The Customers, Bane for The Companies
II-2 All the Strangle for Peanuts? II-3 Factors Affecting the Market II-3
Paclitaxel Versus Abraxane II-3

2. Outlook II-5 Bulk Paclitaxel - Great Future Ahead II-5 Competitive Scenario
II-5 Cancer Generics - A Time for Optimism II-5 The US Piazza II-6

3. Product Overview II-7 Chemical Properties II-7 Sourcing II-7 From Natural
Sources II-8 Yew Trees II-8 From Semi-Synthesis Process II-8 Mechanism of Action
II-8 History of Paclitaxel and its Discovery as an Anti-Cancer Agent II-9 China
Wins Laurels for Supply of Natural Paclitaxel II-10 Hazelnut Trees Emerge as the
Alternate Source of Paclitaxel II-10 Taxol - The Uncrowned Leader II-11
Paclitaxel - Concerns II-11 Abraxane and Tocosol: Set to Ride the Market Duel?
II-11 Many Faces (Phases) of Paclitaxel - The Variants II-12 Taxotere - A
Potential Competitor to Paclitaxel II-12

4. Research and Development II-13 Angiotech Unfurls New Dimensions for
Paclitaxel II-13 Clinical Research Favors Paclitaxel for Breast Cancer Treatment
II-13 American BioScience` Nab Technology Unveils Higher Tissue Penetration
Potential II-13 Naturol Develops Unique Extraction Technology for Producing
Paclitaxel from Canadian Yew II-14 Ivax Corp.`s Xorane Revolutionizes the
Delivery of Paclitaxel II-14

5. Product Launches/Introductions II-15 Dabur Launches Cancer Drug. II-15 Dabur
Introduces Nanoxel. II-15 Nippon Introduces Paclitaxel Injection NK. II-15

6. Recent Industry Activity II-16 Sonus to Merge with OncoGenex II-16 Acusphere
Signs Licensing Deal with Cephalon II-16 Sonus Terminates TOCOSOL Paclitaxel
Development Program II-16 Eagle Pharmaceuticals to Develop and Market Tocosol
Paclitaxel II-16 Pliva Lachema Receives ANDA for Paclitaxel Injection II-16 Cell
Therapeutics Receives EMEA Acceptance II-17 Abraxis Wins Approval for ABRAXANE
in Korea II-17 Boston Scientific Obtains Approval for TAXUS Liberte from Health
Canada . II-17 Cell Therapeutics Renames Xyotax as Opaxio II-17 Hospira Takes
Over Mayne Pharma II-17 Protherics to Acquire MacroMed II-17 Abraxis Acquires
Arizona Production Facility II-18 Indena Inks Worldwide License Agreement with
Spectrum Pharma II-18 Bioxel Bags Major Paclitaxel Order II-18 Bioxel Enters
into Supply Agreement II-18 Bioxel Bags Paclitaxel Supply Contract II-19 Indena
Establishes New Plant to Produce Synthetic Paclitaxel II-19 Abraxis Selects
Korean Green Cross to Market ABRAXANE II-19 Abraxis Grants License to Biocon for
Marketing ABRAXANE II-19 Bioxel Registers Docetaxel with US FDA II-19 Bayer
Quashes TOCOSOL Paclitaxel License with Sonus II-20 Abraxis` ABRAXANE Convinces
European CHMP II-20 Abraxis Receives Approval for ABRAXANE in Australia II-20
Eurocor Receives CE Mark II-20 SuperGen Divests Certain Drugs to Intas II-20
Abraxis Plans Separation of Oncology Business II-20 Teva Acquires IVAX II-21
Mayne to Acquire Nipent and SurfaceSafe Product Rights in North America II-21
Athersys Expands Research Collaboration with Bristol-Myers Squibb II-21 American
Pharmaceutical Partners and American BioScience Combine to Create Abraxis
BioScience II-22 Bioxel Increases its Presence in Europe II-22 Xechem Resolves
Paclitaxel Antitrust Lawsuit with Bristol- Myers Squibb II-22 Angiotech Acquires
American Medical Instruments II-22 Paxis Signs Supply Agreement for Europe and
the United States II-22 Angiotech to Take Over Quill Medical II-22 Bioxel and
Cook Enters Supply Agreement for Paclitaxel II-23 Angiotech Acquires Lifespan
Vascular Graft Business II-23 Bristol-Myers Extends Agreement with Ambit II-23
Angiotech Takes Over Afmedica II-23 Bristol-Myers Squibb Gets European Approval
for Paclitaxel II-23 Angiotech Signs Exclusive License Agreement with CABG
Medical II-24 Conor Medsystems Acquires the Assets of Phytogen Life Sciences
II-24 Sonus Pharmaceuticals and Schering Sign Licensing Agreement. II-24 Sonus`
Tocosol Wins FDA`s ODD II-24 ABI`s Abraxane Wins FDA Approval II-25 SuperGen`s
Paclitaxel Injection Accorded ANDA Status from the USFDA II-25 Ivax Signs
Agreement with Mayne II-25 Integrated Bio Pharma Acquires Hauser CRO II-25 Mayne
Gearing up to Fight it Alone with Proprietary Paclitaxel II-25 Bioxel Inks a
Paclitaxel Supply Deal with CTI II-25 DFB Pharmaceuticals Takes Over Phyton
II-25 NaPro Divests Paclitaxel Business to Faulding II-26 Bioxel-Aerojet`s
Large-Scale Paclitaxel Purification Process Gets FDA`s Nod II-26 Ivax Earns
Expanded Approval for Paxene from the European Commission II-26 Sonus Obtains
Third Patent for the Composition of Tocosol Paclitaxel II-26 Bioxel Forays into
the European Market II-26 Xechem Pockets Additional Patents for Second
Generation Paclitaxel II-27 Dabur Pharma Initiates Phase IIb Trial for
Nanoparticle Delivery Systems II-27 Acusphere Inc. Completes Phase 1 Trial for
AI-850 II-27 Tisorex Changes Name to Paxis Pharmaceuticals II-27

7. Focus on Select Global Players II-28 Abraxis BioScience, Inc. (USA) II-28
Bioxel Pharma Inc. (Canada) II-28 Bristol-Myers Squibb Co. (USA) II-28 Hospira,
Inc. (USA) . II-28 Indena S.p.A. (Italy) II-29 OncoGenex Pharmaceuticals, Inc.
(USA). II-29 Teva Pharmaceuticals USA, Inc. (USA) . II-29 Xechem International
Inc. (USA) II-30

8. Global Market Perspective II-31

Table 1: World Recent Past, Current & Future Analysis for Bulk Paclitaxel by
Geographic Region - US and Rest of World Markets Independently Analyzed with
Annual Sales in Kilograms for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-31

Table 2: World Long-term Projections for Bulk Paclitaxel by Geographic Region -
US and Rest of World Markets Independently Analyzed with Annual Sales in
Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart) II-32

Table 3: World Recent Past, Current & Future Analysis for Bulk Paclitaxel by
Geographic Region - US and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-33

Table 4: World Long-term Projections for Bulk Paclitaxel by Geographic Region -
US and Rest of World Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-34

Table 5: World 10-Year Perspective for Bulk Paclitaxel by Geographic Region -
Percentage Breakdown by Volume Sales for US and Rest of World Markets for Years
2003, 2008, & 2012 II-35

Table 6: World 10-Year Perspective for Bulk Paclitaxel by Geographic Region -
Percentage Breakdown by Dollar Sales for US and Rest of World Markets for Years
2003, 2008, & 2012 II-35

III. MARKET

1. The United States III-1 A.Market Analysis III-1 Current and Future Analysis
III-1 Rising Demand for Paclitaxel III-1 Alarming Growth of Breast Cancer III-1
Clinical Research Favors Paclitaxel for Breast Cancer Treatment III-1 Paclitaxel
- An Important Element III-2 Corporate Talk III-2 Drug-Eluting Stents - Marching
Ahead III-2 Strategic Corporate Developments III-2 Key Players III-7 B.Market
Analytics III-10

Table 7: US Recent Past, Current & Future Analysis for Bulk Paclitaxel Market
with Annual Sales in Kilograms for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-10

Table 8: US Long-term Projections for Bulk Paclitaxel Market with Annual Sales
in Kilograms for Years 2011 through 2015.(includes corresponding Graph/Chart)
III-10

Table 9: US Recent Past, Current & Future Analysis for Bulk Paclitaxel Market
with Annual Sales in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-11

Table 10: US Long-term Projections for Bulk Paclitaxel Market with Annual Sales
in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
III-11

2. Rest of World III-12 A.Market Analysis III-12 Current and Future Analysis
III-12 Europe. III-12 European Market Overview III-12 European Market Battling
Cost-Containment Woes III-12 Efforts to Improve the Scenario and their Effect on
Paclitaxel Market III-13 China. III-13 Chinese Government Strategizing to Save
Paclitaxel Reserves III-13 Product Launches/Developments. III-13 Strategic
Corporate Development III-14 Key Players III-20 B.Market Analytics III-22

Table 11: Rest of World Recent Past, Current & Future Analysis for Bulk
Paclitaxel Market with Annual Sales in Kilograms for Years 2000 through 2010
(includes corresponding Graph/Chart) III-22

Table 12: Rest of World Long-term Projections for Bulk Paclitaxel with Annual
Sales in Kilograms for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-22

Table 13: Rest of World Recent Past, Current & Future Analysis for Bulk
Paclitaxel Market with Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-23

Table 14: Rest of World Long-term Projections for Bulk Paclitaxel Market with
Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart). III-23

IV. COMPETITIVE LANDSCAPE

The Companies mentioned inside this report include:-Abraxis Bioscience, Inc
(USA) -Acusphere, Inc (USA) -Ambit Biosciences Corporation (USA) -Angiotech
Pharmaceuticals, Inc (Canada) -Aphios Corporation (USA) -Athersys, Inc (USA)
-Atlantis Bioactives Corporation (Canada) -Ben Venue Laboratories, Inc (USA)
-Bedford Laboratories, Inc (USA) -Bioxel Pharma, Inc (Canada) -Bristol-Myers
Squibb Company (USA) -Cell Therapeutics, Inc (USA) -Conor Medsystems, Inc (USA)
-Phytogen Life Sciences, Inc (Canada) -Cook, Inc (USA) -Dabur India Ltd (India)
-DFB Pharmaceuticals, Inc (USA) -Phyton Biotech, Inc (USA) -Fermentek Ltd
(Israel) -Indena SpA (Italy) -Integrated Biopharma, Inc (USA) -Korea United
Pharm, Inc (Korea) -Mylan Laboratories, Inc (USA) -Natural Pharmaceuticals, Inc
(USA) -Samyang Genex Corporation (Korea) -Sanofi-Aventis (France) -Shanghai
Jinhe Bio-Technology Co, Ltd (China) -Sonus Pharmaceuticals, Inc (USA)
-Supergen, Inc (USA) -Symbion Health Limited (Australia) -Mayne Pharma (USA),
Inc (USA) -Taxolog, Inc (USA) -Teva Pharmaceutical Industries Ltd (Israel)
-Xechem International, Inc (USA) -Xian Tiancheng Drugs & Bioengineering Co, Ltd
(China)

To order this report:World Bulk Paclitaxel Market

http://www.reportlinker.com/p098262/World-Bulk-Paclitaxel--Market.html

More market research reports here!

Reportlinker
Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

Copyright Business Wire 2009